These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
501 related articles for article (PubMed ID: 12181274)
1. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years. Kawaguchi K; Oda Y; Sakamoto A; Saito T; Tamiya S; Iwamoto Y; Tsuneyoshi M Mod Pathol; 2002 Aug; 15(8):878-88. PubMed ID: 12181274 [TBL] [Abstract][Full Text] [Related]
2. Molecular analysis of p53, MDM2 and H-ras genes in low-grade central osteosarcoma. Park HR; Jung WW; Bertoni F; Bacchini P; Park JH; Kim YW; Park YK Pathol Res Pract; 2004; 200(6):439-45. PubMed ID: 15310147 [TBL] [Abstract][Full Text] [Related]
3. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma. Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040 [TBL] [Abstract][Full Text] [Related]
4. p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate. Lonardo F; Ueda T; Huvos AG; Healey J; Ladanyi M Cancer; 1997 Apr; 79(8):1541-7. PubMed ID: 9118036 [TBL] [Abstract][Full Text] [Related]
5. Retroperitoneal liposarcoma with combined well-differentiated and myxoid malignant fibrous histiocytoma-like myxoid areas. Hisaoka M; Morimitsu Y; Hashimoto H; Ishida T; Mukai H; Satoh H; Motoi T; Machinami R Am J Surg Pathol; 1999 Dec; 23(12):1480-92. PubMed ID: 10584701 [TBL] [Abstract][Full Text] [Related]
7. Amplification of the CDK4 gene in sarcomas: tumor specificity and relationship with the RB gene mutation. Kanoe H; Nakayama T; Murakami H; Hosaka T; Yamamoto H; Nakashima Y; Tsuboyama T; Nakamura T; Sasaki MS; Toguchida J Anticancer Res; 1998; 18(4A):2317-21. PubMed ID: 9703873 [TBL] [Abstract][Full Text] [Related]
8. Osteosarcoma versus malignant fibrous histiocytoma of bone in patients older than 40 years. A clinicopathologic and immunohistochemical analysis with special reference to malignant fibrous histiocytoma-like osteosarcoma. Naka T; Fukuda T; Shinohara N; Iwamoto Y; Sugioka Y; Tsuneyoshi M Cancer; 1995 Sep; 76(6):972-84. PubMed ID: 8625223 [TBL] [Abstract][Full Text] [Related]
9. Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma. Mejia-Guerrero S; Quejada M; Gokgoz N; Gill M; Parkes RK; Wunder JS; Andrulis IL Genes Chromosomes Cancer; 2010 Jun; 49(6):518-25. PubMed ID: 20196171 [TBL] [Abstract][Full Text] [Related]
10. Analysis of p53 and mdm2 proteins in malignant fibrous histiocytoma in absence of gene alteration: prognostic significance. Molina P; Pellín A; Navarro S; Boix J; Carda C; Llombart-Bosch A Virchows Arch; 1999 Dec; 435(6):596-605. PubMed ID: 10628802 [TBL] [Abstract][Full Text] [Related]
11. Analysis of central regulatory pathways in p53-deficient primary cultures of malignant fibrous histiocytoma exposed to ifosfamide. Schlott T; Taubert H; Fayyazi A; Schweyer S; Bartel F; Korabiowska M; Brinck U Anticancer Res; 2004; 24(6):3819-29. PubMed ID: 15736417 [TBL] [Abstract][Full Text] [Related]
12. Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma. Takahashi Y; Oda Y; Kawaguchi K; Tamiya S; Yamamoto H; Suita S; Tsuneyoshi M Mod Pathol; 2004 Jun; 17(6):660-9. PubMed ID: 15098008 [TBL] [Abstract][Full Text] [Related]
13. p53 and ras mutations in Ewing's sarcoma. Radig K; Schneider-Stock R; Röse I; Mittler U; Oda Y; Roessner A Pathol Res Pract; 1998; 194(3):157-62. PubMed ID: 9587933 [TBL] [Abstract][Full Text] [Related]
14. p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations. Villuendas R; Pezzella F; Gatter K; Algara P; Sánchez-Beato M; Martínez P; Martínez JC; Muñoz K; García P; Sánchez L; Kocialkowsky S; Campo E; Orradre JL; Piris MA J Pathol; 1997 Jan; 181(1):51-61. PubMed ID: 9072003 [TBL] [Abstract][Full Text] [Related]
15. Atypical fibroxanthoma versus benign and malignant fibrous histiocytoma. A comparative study of their proliferative activity using MIB-1, DNA flow cytometry, and p53 immunostaining. Oshiro Y; Fukuda T; Tsuneyoshi M Cancer; 1995 Mar; 75(5):1128-34. PubMed ID: 7850711 [TBL] [Abstract][Full Text] [Related]
16. Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity. Coindre JM; Hostein I; Maire G; Derré J; Guillou L; Leroux A; Ghnassia JP; Collin F; Pedeutour F; Aurias A J Pathol; 2004 Jul; 203(3):822-30. PubMed ID: 15221942 [TBL] [Abstract][Full Text] [Related]
17. Genetic analysis of fibrosarcoma of bone, a rare tumour entity closely related to osteosarcoma and malignant fibrous histiocytoma of bone. Hattinger CM; Tarkkanen M; Benini S; Pasello M; Stoico G; Bacchini P; Knuutila S; Scotlandi K; Picci P; Serra M Eur J Cell Biol; 2004 Sep; 83(9):483-91. PubMed ID: 15540465 [TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic implications of MDM2, p53 and K-ras gene alterations in osteosarcomas: MDM2 amplification and p53 mutations found in progressive tumors. Yokoyama R; Schneider-Stock R; Radig K; Wex T; Roessner A Pathol Res Pract; 1998; 194(9):615-21. PubMed ID: 9793960 [TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical status of p53, mdm2 and Ki-67 in malignant fibrous histiocytoma. Szadowska A; Olborski B; Harezga-Bal B; Debiec-Rychter M Pol J Pathol; 1998; 49(1):15-21. PubMed ID: 9640970 [TBL] [Abstract][Full Text] [Related]
20. A new subtype of high-grade mandibular osteosarcoma with RASAL1/MDM2 amplification. Guérin M; Thariat J; Ouali M; Bouvier C; Decouvelaere AV; Cassagnau E; Aubert S; Lepreux S; Coindre JM; Valmary-Degano S; Larousserie F; Meilleroux J; Projetti F; Stock N; Galant C; Marie B; Peyrottes I; de Pinieux G; Gomez-Brouchet A Hum Pathol; 2016 Apr; 50():70-8. PubMed ID: 26997440 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]